Co-Diagnostics Implements Reverse Stock Split to Maintain Nasdaq Listing Compliance
Co-Diagnostics Enacts Reverse Stock Split
Co-Diagnostics, Inc., a Utah-based molecular diagnostics company listed on Nasdaq under the ticker symbol CODX, has announced a strategic move to implement a reverse stock split. This decision comes as the company aims to align with the regulatory requirements for continued trading on the Nasdaq Capital Market. The reverse stock split will be executed at a ratio of 1-for-25, meaning that for every 25 shares currently held, stockholders will receive one new share effective from 12:01 AM ET on November 24, 2026.
Purpose of the Reverse Stock Split
The primary motivation behind this corporate action is to ensure that Co-Diagnostics meets the minimum bid price requirement of $1.00, a crucial threshold for maintaining its listing on Nasdaq. As per the company’s filings, this split is expected to enhance the trading value of its stock, thereby increasing investor confidence. Additionally, the move is designed to provide Co-Diagnostics with more flexibility regarding its stock, allowing for potential equity financing opportunities if needed in the future.
Details of the Amendment
The reverse stock split was sanctioned by the stockholders during a Special Meeting held on November 13, 2026. At this meeting, stockholders approved an amendment to the Articles of Incorporation, which provides the Company's board with the discretion to execute additional reverse stock splits if necessary, with the cumulative effect not exceeding a 1-for-750 ratio. This measure offers operational leeway within the upcoming year without requiring further stockholder approval.
Implications for Shareholders
As part of the reverse stock split process, shareholders will observe a reduction in the total number of shares they own, although the overall value of their investment should theoretically remain unchanged. Following the implementation of the split, approximately 521,779 shares are anticipated to be outstanding based on the current total of 13,044,465 shares. Historical stock performance and the share price movements prior to the split will contribute to the new valuation of shares.
For any fractions not resulting in a whole number of shares, Co-Diagnostics will round up to the nearest whole share, ensuring that shareholders do not end up with insignificant fractions of shares. Owners of shares in brokerage accounts should clarify details regarding the split with their respective brokers.
Company Overview and Future Outlook
Co-Diagnostics, Inc. specializes in developing, manufacturing, and marketing advanced diagnostic technologies that utilize nucleic acid detection methodologies, including DNA and RNA tests. The company’s innovations in diagnostics reflect its commitment to tackling various health challenges through precise and advanced testing solutions.
In a continually evolving market, the move to conduct a reverse stock split signals Co-Diagnostics' proactive approach to uphold its market position while exploring future growth avenues. Despite the potential uncertainties accompanying a reverse stock split, the management remains optimistic about the company's strategic roadmap and future equity financing projects.
In summary, as Co-Diagnostics undertakes this important step in its corporate strategy, it will remain focused on delivering quality diagnostic solutions that meet current market needs and improving shareholder value in the long run.